Intercept Pharmaceuticals Inc (ICPT) Dividend History

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis now called primary biliary cholangitis, non-alcoholic fatty liver disease , cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. The company's lead product is obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva. OCA is a potent first-in-class farnesoid X receptor agonist. As of March 2017, Ocaliva is approved in the US and the EU for use in primary biliary cholangitis. It is in phase III studies for non-alcoholic steatohepatitis and phase II studies for primary sclerosing cholangitis.

Last update 05/29/2023

Dividend Yield Summary

  2018 2019 2020 2021 2022 2023
Dividends - - - - - -
Average Price 85.89 88.62 61.27 20.05 15.48 16.59
Yield - - - - - -
• The above Dividend, Average Price, and Yield values for 2023 are year-to-date.

Dividend History

No history of dividends
Date Amount Per Share Note